Understanding Tysabri and PML: A Monitoring Guide for Pennsylvania Patients

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or a loved one is taking Tysabri (natalizumab), you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection. This concern builds on a long history of patient education about biologic therapies and their potential long-term effects. This guide explains the essential follow-up exams and tests used to monitor for PML, helping you have informed discussions with your healthcare provider.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus (JCV) and typically occurs only in patients who are immunocompromised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label identifies three risk factors for PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can be subtle and variable, often including progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. FDA adverse-event reports for Tysabri frequently list fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, balance disorder, hypoesthesia, muscular weakness, cognitive disorder, and mobility decreased (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). Many of these symptoms overlap with PML, making early diagnosis challenging. Healthcare professionals are instructed to monitor patients on Tysabri for any new sign or symptom suggestive of PML and to withhold dosing immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read the Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism of PML Development and Legal Implications

The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. By blocking the adhesion molecule VLA-4, Tysabri prevents lymphocytes from crossing the blood-brain barrier, thereby reducing immune surveillance in the central nervous system. This immunosuppressive effect in the brain allows latent JC virus to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The duration of treatment prior to PML onset can range from a few months to several years, as noted in the label for herpes infections, which also occur with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This timeline is critical for understanding the exposure-harm relationship in legal contexts. For patients in Pennsylvania who have developed PML after Tysabri treatment, attorney-related considerations include the statute of limitations for filing a product liability or medical malpractice claim. In Pennsylvania, the statute of limitations for personal injury actions is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, the date of discovery may be when a definitive diagnosis is made via MRI and cerebrospinal fluid PCR for JCV DNA. However, because PML symptoms can mimic multiple sclerosis relapses, the discovery date may be contested. The adequacy of warnings regarding Tysabri and PML is a central issue in such cases. The boxed warning clearly states the increased risk and identifies risk factors, but questions may arise about whether prescribers and patients were adequately informed about the magnitude of risk, the need for regular monitoring, and the importance of risk stratification based on anti-JCV antibody status and treatment duration. The TOUCH program is designed to ensure informed consent, but compliance and communication gaps can occur. The timeline between Tysabri exposure and documented harm is also relevant. PML typically develops after months to years of treatment, with risk increasing beyond 2 years. This latency period can complicate the identification of the responsible party and the timing of the injury. For legal purposes, it is essential to document the start and end dates of Tysabri therapy, the date of PML diagnosis, and any intervening factors such as prior immunosuppressant use. The FDA adverse-event reporting system (FAERS) data show that Tysabri is associated with a wide range of neurological and systemic adverse events, but PML remains the most serious and distinctive harm (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). In summary, the medical evidence establishes a clear causal link between Tysabri and PML, with well-defined risk factors and a plausible mechanistic pathway. For Pennsylvania patients and their attorneys, the statute of limitations, adequacy of warnings, and exposure timeline are critical factors in pursuing legal recourse. The boxed warning and TOUCH program provide a framework for risk communication, but individual circumstances may warrant careful evaluation of whether these measures were sufficient to prevent harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Pennsylvania?

In Pennsylvania, the statute of limitations for personal injury actions is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, the discovery date is typically when a definitive diagnosis is made via MRI and cerebrospinal fluid PCR for JCV DNA. However, because PML symptoms can mimic multiple sclerosis relapses, the discovery date may be contested. It is crucial to consult with an attorney promptly to preserve your legal rights.

What are the known risk factors for developing PML while on Tysabri?

The prescribing information for Tysabri identifies three key risk factors for PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.